Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Dec 09, 2022 2:43pm

280 Views

Post# 35162437

The long wait hereon ... nothing else unless a surprise

Overall, we have positive momentum based on two interim trials:

Goblets
Adlai

They both suggest that Bracelet will be highly successful.

Can we guess the outcome?

Yes. Time is our ally. Everyday where there is no new means that the results will be positive(efficacy based on extension of life).

Share pricce will naturally increase as we get closer to ASCO (June).
General rule of thumb market anticipate 60 to 80% valuation for PIII equivalent.
So, I guess it quite possible we see 5 or 6$ near term.

<< Previous

Bullboard Posts

Next >>

First Nations contributions attract investor interest